As we rapt this decare, a small group of companies 23andMe, its Silicon Valley neighbor Navigenics, and Icelandic opponent deCODE Genetics was selling a posterior of personalized medicine. Patients would take the keys to longer and well lives by realizing the hazards mentioned in their DNA and working with their doctors to decrease them.
23abdMe cofounder Anne Wojcicki told the Time magazine that they all carry this information, and if they fetch it together and democratize it, they could change the health care. Still, in reality, the 2010s would be when genetics got communal. As the decade comes to a closure, few have discussed the genes with the doctors, but millions have uploaded DNA profiles to online databases.
Anne also stated that it is become like Facebook for genes, guided by the same fundamental human wish to connect. As with Mark Zuckerberg’s social media behemoth, this is the decade they reckoned with what it means to transfer some of the essential data in the procedure. It all planned out differently from the way she imagined in 2009 when she paid $985 to deCODE and $399 to 23andME to put her DNA into the service of science journalism. Anne was conspired by the potential of DNA testing for personalized medicine, but from the starting, she was also tensed about privacy. She imagined a future in which people could steal medical secrets by testing the DNA.
23andMe, helped by the deep pockets of Google and other Silicon Valley investors, had sufficient cash to continue. But it fell obscene of the FDA, that had decided that the company was selling medical devices that required official permission to be put on the market. In a 2013 warning letter, the FDA stated that 23andME had ruined to offer enough evidence that its tests emanated accurate results. By the end of 2013, 23andMe had confined offering assessments of health risks to new customers. Since then, the company has slowly clawed it’s way back into the health business.